Regeneron Pharmaceuticals, Inc. REGN is looking to make inroads in the lucrative obesity market. The company recently entered ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; ...

The candidate is being positioned as a potential oral competitor to Sanofi and Regeneron's blockbuster Dupixent in allergy ...

French drugmaker adds Ayvakit and next-gen immunology pipeline in strategic move to dominate rare disease space Sanofi has ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

For investors still seeking companiies with attractive long-term prospects, let's consider two in the biotech industry: ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Kymera Therapeutics reported that an experimental drug designed to rival Sanofi and Regeneron’s blockbuster therapy Dupixent ...

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.